Biomarker discovery and screening platform introduces proteomic signature technology that delivers high throughput and ultra-high mass accuracy and stability for high-confidence proteomic signatures
PerkinElmer has announced the launch of its Bioxpression biomarker discovery and screening platform at the 53rd American Society for Mass Spectrometry (ASMS) conference in San Antonio, Texas.
It says the platform provides a complete solution that can speed the discovery of biomarkers through its unique biomarker sample enrichment technology and highly accurate mass pattern recognition approach.
The Bioxpression platform introduces new proteomic signature technology (PST) that delivers high throughput and ultra-high mass accuracy and stability, resulting in comprehensive and high-confidence proteomic signatures.
"Using advanced, innovative technologies, PerkinElmer has developed a suite of tools that provides the maximum meaningful data from multiple samples, improving confidence in results and reproducibility," said Peter Coggins, president of PerkinElmer Life and Analytical Sciences.
"This comprehensive platform extends our well-established leadership in biomarker discovery and screening technology".
The Bioxpression biomarker platform includes the Protof 2000 Maldi-Tof mass spectrometer, Proxpression carrier protein-based blood biomarker enrichment kits, and Bamf technology from Predictive Diagnostics.
Two new components, a Maldi calibration kit and a standardisation kit, which will provide uniformity across multiple instrument platforms, were also launched at the show.
Recently, PerkinElmer and Predictive Diagnostics used the Bioxpression biomarker platform to identify a series of biomarkers that appear to differ in persons with Alzheimer's Disease compared to persons without cognitive impairment.
The study is the first of its kind to describe a potential diagnostic blood test for Alzheimer's disease.
